Clinuvel Pharmaceuticals has released a quarterly activity report

Industry News

& Articles

Clinuvel Pharmaceuticals releases quarterly activity report

Facebooktwitterlinkedin

Clinuvel Pharmaceuticals (ASX: CUV) has released strong results in a quarterly activity report, citing that the COVID-19, has and will continue to impact their operations worldwide. The report discussed Clinuvel’s sound financial position and management of the pandemic, attributing its success to the growing distribution and sale of SCENESSE. SCENESSE is a pain-free skin treatment for adult patients with phototoxic reactions.

Clinuvel is an Australian based company, established in 1987 specializing in skin care medication. They sell their products around the world and have been expanding into the US and European markets, in particular.

The Quarterly activity report released to the ASX today, outlined cash receipts of $10.4 million and Net Cash flows of $7.175 million all relating to the supply of SCENNESE. The increased focus on the new medication led the company to raise capital in Europe, reflecting a seven per cent increase in cash reserves from $14.17 million to $66.747 million from March to June 2020. Despite the impacts of COVID-19, the report states that the demand for the drug remained high and is trending positively upwards. In April SCENNSE also began distribution in the United States.

Clinuvel’s current financial position allows them to continue their development and expansion of future clinical initiatives to treat severe genetic and skin disorders. Clinuvel’s Chief Executive Officer Mr Darren Keemy believes Clinuvel will be “able to respond to changes quickly and nimbly, limiting the need to return to investors to access capital and allowing us to focus on the long-term growth of the Group.”

Looking ahead, the skincare treatment company is in a strong financial position to manage current economic positions. They are in the process of finalizing clinical study protocols to begin testing treatments for vitiligo, a disease that affects between 0.5-2 per cent. They summarize their strategy in 2020 into three areas: Commercial growth and expansion, a pipeline of new products and Inorganic growth. Together they will support Clinuvel’s “evolution into a vertically integrated pharmaceutical company.”

Currently, Clinuvel is trading at $22.29 (as of 31st July, 12pm) 20 per cent below their year to date highs. However, the company has recovered 70 per cent of its value from March lows at $12.80. Clinuvel Pharmaceuticals release of the quarterly activities report has underwhelmed investors sending the stock down 0.22 per cent. The company warned that the pharmaceutical industry is not immune to international conditions. However, “Against the Global economic contraction, CLINUVEL is the best positioned to invest in its planned growth and expansion, and patient demand for treatment,” Mr Keamy said. Audited financial reports will be released on the 31st of August.

Caroline Wong

Caroline Wong is a Research Analyst at KOSEC – Kodari Securities. She writes on markets and focuses on ASX Top 300 companies. Email Caroline at c.wong@kosec.com.au.

Comment on this company

Latest Stories

Macmahon Wins Coburn Mineral Sands Project

Macmahon Holdings Limited (ASX: MAH) has revealed on the 3rd of August, that it has.. …

Magellan Announces Global Equity Fund Restructure

Magellan Financial Group has announced that they will restructure the retail product.. …

Infigen Updates Fourth Quarter FY20 Operations

Infigen Energy (ASX:IFN) releases its quarterly activity report for the three months ending 30 June 2020……

More for you

Origin Energy Posts Resilient Fourth Quarter Results

On the 31st of July 2020, Origin Energy (ASX: ORG) releases its quarterly report which details.. …

CIMIC Group Reports HY20 Performance

Cimic Group Limited (ASX:CIM) releases its half-year performance for the six months to 30 June 2020, highlighting……

Fortescue Metals Reports Record Iron Ore Shipments

Fortescue Metals Group (ASX: FMG), as of the 30th of July released their June 2020… …

Macquarie Group Reports fall in profits of 8 per cent

Macquarie Group has reported an 8 per cent decline in profits in the FY20 financial year at $2.731 billion……

Nickel Mines Releases Quarterly Activities Report

Nickel Mines Limited (ASX:NIC) has released a quarterly operations statement for the quarter……

CIMIC Group Signs Agreement with Elliott Advisors

As of the 29th of July, CIMIC Group (ASX: CIM) is entering exclusive negotiations with.. …

KOSEC Terms & Conditions

Kodari Securities Pty Ltd (CAR 399556) trading as KOSEC is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC is a financial services company and any information provided by its platforms, portals, reports and documents is protected by copyright. Any unauthorised production of this information is prohibited.
KOSEC reserves the right to change or remove any information provided on our website, reports or any documents including these terms and conditions at any time without notice. The change or modification to the terms and conditions will be effective immediately upon posting an updated version on our website, necessary platforms and documents. It is recommended that you review the information provided on our website, including these terms and conditions frequently for any changes.

Disclaimer
KOSEC provides general advice only. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. KOSEC recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Please make sure you read our Financial Services Guide (FSG).

KOSEC does not guarantee any returns. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance). Investing in the stock market can incur huge losses. Please also be aware that fees will incur on every transaction regardless of the performance of your investments or returns generated. Employees and or associates of KOSEC may hold one or more of the stocks, securities or investments reviewed by the company.

Your use of information from our website, reports, documents and from talking to our representatives/associates is at your risk. Under no circumstance should the investment be based solely on KOSEC information and general advice. You should seek professional financial planning advice.
KOSEC aims to maintain the accuracy of the data and information provided on this website, by using information prepared from a wide variety of sources, which KOSEC to the best of its knowledge and belief, considers accurate and does not make any representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.

We may at times refer to third parties, which the details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market. KOSEC has no control over the information third parties have, or the products or services offered, and therefore make no representations regarding the accuracy or suitability of such information, products or services. You are advised to make your own enquiries in relation to third parties. Our inclusion of any third party content is not an endorsement of that content or the third party.

Fees
As a client you will be charged a yearly service fee and a set brokerage fee per transaction. Your service fee will automatically renew at the end of your agreed 12 month period at the same rate advertised at the time. Your credit card or bank account will be charged for a further year following which will again auto renew until you cancel your yearly service fee. You can cancel the auto renewal at any time in advance of the renewal date by contacting us. KOSEC is aware of the need to ensure the security of your credit card details and our payment systems are compliant with the Payment Card Industry (PCI) Data Security Standard.

Privacy
You consent to receiving email correspondence from KOSEC, as well as companies KOSEC has an association with. These emails will be sent by KOSEC and third party companies. You can opt out of receiving any category of emails at any time by contacting us. We may from time to time inform you of special offers, or even ask your opinion of the services we provide, but your involvement is optional. Should you request us to do so, we will archive your details.

Indemnity and Liability
You indemnify KOSEC from all claims or threatened claims, suits, demands, damages, costs as well as including legal costs incurred in dealing with any threatened claim, expenses made by any person or corporation against KOSEC and any other amounts which is caused by KOSEC providing information, execution and General Advice.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from a decision made by you on the basis of information obtained through the use of our portal, reports, documents or any General Advice given and any transaction taken place.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from delays in executing orders for the client and acknowledges KOSEC makes no guarantees about the time taken to execute an order on behalf of the client. You acknowledge that KOSEC relies on third parties in providing technology and release KOSEC from any harm, loss or damage you may suffer as a result of the failure of such information technology.

Cookies and Links
KOSEC website, and its portal uses cookies, which lets us identify your browser while you are using the site or our portal. Cookies do not identify you personally. They simply allow us to track your usage patterns. If you prefer not to receive cookies, you can configure your browser to reject them or to notify you when they are being used. The functionality of the KOSEC website may be impacted if you restrict the use of cookies.

Fill up the form below and we will get back to you as soon as possible.

CLAIM YOUR FREE E-BOOK &
7 DAY ACCESS TO LOTUS BLUE

STOCK MARKET SUCCESS

KOSEC’s CEO, Michael Kodari’s new book, “Stock Market Success” valued at $39.95, available at Dymocks book stores with all the proceeds going to Dymocks Children’s Charities.

CLAIM YOUR FREE E-BOOK WHEN YOU LOGIN TO LOTUS BLUE INVESTMENT PORTAL

Latest TV Commercial